News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alnylam Pharmaceuticals (ALNY) and Collaborators Publish New Pre-clinical Results on Ex Vivo Applications of RNAi to Enhance Dendritic Cell Vaccines for Cancer


8/22/2012 10:40:29 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and collaborators at Radboud University Nijmegen Medical Centre in the Netherlands announced today that they have published new pre-clinical results in the journal Cancer Immunology Immunotherapy (doi:10.1007/s00262-012-1334-1) describing the development of a dendritic cell (DC) cancer vaccine with enhanced immunogenic potential. The findings show that ex vivo RNAi targeting of the programmed death ligands (PD-L1 and PD-L2) can significantly boost the immunogenicity of DC-based vaccines. These results could lead to the development of improved cellular vaccine therapies for the treatment of cancer and chronic viral infections.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES